Spacelabs Medical
This article was originally published in The Gray Sheet
Executive Summary
Successor for outgoing Chairman, President and CEO Carl Lombardi is being sought by the firm's strategic planning committee; the exec plans to retire in May 2002 after 35 years with the company. The Redmond, Washington patient monitor maker also notes that it has retained investment banking firm Gerard Klauer Mattison to "explore strategic alternatives." Defibrillator firm Cardiac Science dropped a $15-per-share bid for the company in January citing a lack of interest from Spacelabs' board and management. Spacelabs stock closed at $12.39 on the Dec. 13 announcement, up 8.7%...
You may also be interested in...
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.